TOPICAL INSULIN FOR GLAUCOMA, Phase 1

• Status: Not yet recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Capable to provide informed consent

• Diagnosis of optic neuropathy either glaucoma or NAION or optic disc drusen.

• Only one eye per patient will be selected as the study eye - if both eyes meet the inclusion criteria, the eye with the worse acuity and /or visual field will be selected. The contralateral eye will be left untouched.

Exclusion Criteria:

• Pregnant or breastfeeding woman

• Presence of any ocular pathologies other than glaucoma that contributes to the severe vision loss (retinopathy / maculopathy, severe uveitis, keratopathy, etc.)

• Diagnosis of glucose intolerance, type 1 or 2 diabetes mellitus

• Inability to perform reliable visual field

• Unable to provide informed consent

• Unable to complete the tests and follow-ups required by the study